BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu B, Hu X, Feng J, Geng C, Jin F, Li H, Li M, Li Q, Liao N, Liu D, Liu J, Liu Q, Lu J, Liu Z, Ma F, Ouyang Q, Pan Y, Shen K, Sun T, Teng Y, Tong Z, Wang B, Wang H, Wang S, Wang S, Wang T, Wang X, Wang X, Wang Y, Wang Z, Wu J, Yan M, Yang J, Yin Y, Yuan P, Zhang J, Zhang P, Zhang Q, Zheng H. Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). Cancer 2020;126:3867-82. [DOI: 10.1002/cncr.32832] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen Z, Ouyang Q, Wang Y, Wang J, Wang H, Wu X, Zhang P, Huang J, Zheng Y, Cao W, Shao X, Xie N, Tian C, Liang H, Wang C, Zhang Y, Ren D, Wang X. Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China. Front Oncol 2022;12:829693. [PMID: 35311126 DOI: 10.3389/fonc.2022.829693] [Reference Citation Analysis]
2 Bulska-będkowska W, Czajka-francuz P, Jurek-cisoń S, Owczarek AJ, Francuz T, Chudek J. The Predictive Role of Serum Levels of Soluble Cell Adhesion Molecules (sCAMs) in the Therapy of Advanced Breast Cancer—A Single-Centre Study. Medicina 2022;58:153. [DOI: 10.3390/medicina58020153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Xie Y, Ma J, Xia X, Zheng H, Gou Q. Prognosis and Treatment of Metastatic Breast Cancer From A Real-World Scenario in China: A Retrospective Cohort Study. Cancer Control 2022;29:10732748221130568. [PMID: 36164749 DOI: 10.1177/10732748221130568] [Reference Citation Analysis]
4 Luo Y, Wu W, Zha D, Zhou W, Wang C, Huang J, Chen S, Yu L, Li Y, Huang Q, Zhang J, Zhang C. Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents. Bioorg Med Chem Lett 2021;47:128230. [PMID: 34186178 DOI: 10.1016/j.bmcl.2021.128230] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Wang X, Shao X, Huang J, Lei L, Huang Y, Zheng Y, Cao W, Chen Z. Exploring the concepts and practices of advanced breast cancer treatment: a narrative review. Ann Transl Med 2021;9:721. [PMID: 33987419 DOI: 10.21037/atm-21-1458] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Li X, Zhang X, Liu J, Shen Y. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study. BMC Cancer 2020;20:1102. [PMID: 33187507 DOI: 10.1186/s12885-020-07593-8] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
7 Xu B, Sun T, Zhang Q, Zhang P, Yuan Z, Jiang Z, Wang X, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Shen K, Yu S, Li H, Tang L, Qiu R; study group of BG01-1323L. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial. Ann Oncol 2021;32:218-28. [PMID: 33188874 DOI: 10.1016/j.annonc.2020.10.600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
8 Khuri FR, O'Regan RM. Progress in breast cancer research amid the COVID-19 gloom. Cancer 2020;126 Suppl 16:3809-10. [PMID: 32710663 DOI: 10.1002/cncr.33046] [Reference Citation Analysis]